Fecal Immunochemical Test to Detect Colorectal Neoplasia in Lynch Syndrome: A Prospective Multicenter Study
FIT at thresholds ≤4.1 μg Hb/g feces may be a promising strategy to postpone colonoscopy in approximately 9 of 10 individuals with Lynch syndrome. Large validation studies that also provide gene variant-specific outcomes should be prioritized.
Authors
- Nanne K.H. de Boer (ORCID: https://orcid.org/0000-0001-8357-9887)
- Maarten Jacobs
- Dewkoemar Ramsoekh
- Margriet Lemmens (ORCID: https://orcid.org/0009-0008-2004-0532)
- Manon C.W. Spaander (ORCID: https://orcid.org/0000-0002-9103-9757)
- Evelien Dekker (ORCID: https://orcid.org/0000-0002-4363-0745)
- Jan Jacob Koornstra (ORCID: https://orcid.org/0000-0001-8400-2131)
- Elsa L. S. A. van Liere (ORCID: https://orcid.org/0000-0003-4826-3443)
- Monique Esther van Leerdam (ORCID: https://orcid.org/0000-0002-5719-3208)
- Gerrit A. Meijer (ORCID: https://orcid.org/0000-0003-0330-3130)
- Beatriz G. Carvalho (ORCID: https://orcid.org/0000-0003-4903-399X)
- Johan Kuijvenhoven (ORCID: https://orcid.org/0000-0002-6802-360X)
Institutions
- University Medical Center Groningen (NL)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- The Netherlands Cancer Institute (NL)
- Spaarne Ziekenhuis (NL)
- Oncode Institute (NL)
- Amsterdam University Medical Centers (NL)
- Cancer Center Amsterdam (NL)
- University of Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.14309/ajg.0000000000003043
- Citations
- 8
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.40
Funders
- Teva Pharmaceutical Industries
- Maag Lever Darm Stichting
- Ipsen
- Norgine